You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
中國第三種新冠候選疫苗在後期研究中有效性達66%
阿思達克 02-09 14:06
巴基斯坦負責國家衛生事務的總理特別助理Faisal Sultan在社交網站上發文指,康希諾生物(06185.HK)的新冠疫苗克威莎TM(ConvideciaTM)在全球開展的多中心三期臨床試驗的中期數據顯示,在巴基斯坦單針接種疫苗28天後,對重症新型冠狀病毒肺炎的保護效力為100%,總體保護效力為74.8%。未發生任何與疫苗相關的嚴重不良反應。

至於基於多個國家的分析,康希諾的疫苗在預防有症狀的新冠疫例方面的有效率為65.7%,預防新冠重症病例方面的有效性為90.98%。他寫道,全球分析包括3萬名參與者和101例新冠確診病例,但沒有透露詳細的情況,比如什麼才算是有症狀的病例,以及這些病例中哪些算重症病例。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account